Economic Burden of Atherosclerotic Cardiovascular Disease in France in 2021: Results From the French Nationwide Claims Database (SNDS)

Speaker(s)

Riche VP1, Wargny M2, Goronflot T2, Schirrbonnans S2, Duret S3, Pouriel M3, Bastien A4, Prax J3, Leux C2, Béliard S5, Ferrières J6, Cariou B7, Costa N8
1Nantes University hospital, Nantes, France, 2Nantes University hospital, Nantes, Nantes, France, 3Novartis, Rueil Malmaison, Rueil Malmaison, France, 4Novartis, Paris, France, 5APHM, Marseille, France, 6Toulouse Rangueil University Hospital, Toulouse, France, 7Nantes Université, CHU Nantes, CNRS, Inserm, l'institut du thorax, Nantes, France, 8Toulouse University Hospital, Toulouse, France

Presentation Documents

OBJECTIVES: Cardiovascular diseases have a high economic burden in France, accounting for more than 10% of healthcare costs. The objective of the study was to assess the impact of atherosclerotic cardiovascular disease (ASCVD) on healthcare costs in France.

METHODS: A retrospective, observational study was conducted using the French nationwide claims database (SNDS), collecting data from 99% of the population. Adult patients with ASCVD were selected based on long-term diseases and hospitalizations coded using ICD-10th, or revascularization procedures, identified between 2012 and 2021.

Healthcare resource utilization and associated costs valued from a collective perspective (overall and associated to ASCVD) were described. Total and mean annual costs per patient in 2021 were estimated in €, including direct medical costs and direct non-medical costs (transports). Average additional cost of ASCVD was also estimated by the difference in healthcare costs observed between the prevalent ASCVD population and the population without ASCVD.

RESULTS: In 2021, 2,206,026 patients (4.95% among 45,082,270 adults) were identified with established ASCVD (mean age: 72.2 (±13.4) yo; 36.9% females).

Total annual healthcare costs were estimated at €20.7 billion (€5.1 billion related to ASCVD), representing in average €9,370 per patient (2,324€ related to ASCVD). Hospitalizations for ASCVD, including rehabilitation care, accounted for over 60% of the total ASCVD annual cost with €3.1 billion, followed by drugs €1.4 billion (27.2%) and outpatient visits €0.5 billion (10.3%). Among ASCVD-related drugs, lipid-lowering therapies represented €187.9 million (13%).

Compared to the general population, adjusting for age and sex, ASCVD led to an average additional healthcare cost of 3,181€ per patient in 2021 (+50%).

CONCLUSIONS: This real-world study highlights the huge economic burden of ASCVD in France, hospitalizations being the primary cost driver. These findings underscore the need for better control of risk factors to prevent recurrence of cardiovascular events and therefore to reduce their economic impact.

Code

EE833

Topic

Economic Evaluation, Study Approaches

Disease

Cardiovascular Disorders (including MI, Stroke, Circulatory)